Apollo Hospitals Enterprise Ltd. has posted an exceptional Q1 FY26 performance, with net profit rising 42% YoY to ₹433 crore and revenue up 15% to ₹5,842 crore. All business segments — hospitals, diagnostics, retail health, and digital platforms — contributed to the growth, supported by margin expansion and capacity enhancement.
Apollo Hospitals Enterprise Ltd., headquartered in Chennai, Tamil Nadu, is a leader in India’s private healthcare industry, operating a network of multispecialty hospitals, diagnostic centers, retail pharmacies, and digital health platforms. Established in 1983, the company’s integrated care model combines clinical excellence with advanced technology, spanning preventive care, diagnostics, complex surgeries, and telehealth services.
For the quarter ended June 30, 2025, Apollo Hospitals reported a 42% year-on-year jump in consolidated net profit to ₹433 crore, compared to ₹305 crore in Q1 FY25. Revenue grew 15% YoY to ₹5,842 crore, while EBITDA surged 26% YoY to ₹852 crore, reflecting strong operational efficiencies and margin gains.
Also Read: Indian Stock Market Declines on January 21, 2025: Apollo Hospitals and Tata Consumer Lead Gains
Apollo Hospitals – Q1 FY26 Performance Snapshot
| Segment / Metric | Q1 FY26 | Q1 FY25 | Change (YoY) |
| Total Revenue | ₹5,842 crore | ₹5,079 crore | +15% |
| Net Profit | ₹433 crore | ₹305 crore | +42% |
| EBITDA | ₹852 crore | ₹676 crore | +26% |
| Hospital Services Revenue | ₹2,935 crore | ₹2,644 crore | +11% |
| Hospital EBITDA Margin | 24.5% | 23.5% | +100 bps |
| Digital & Pharmacy Revenue | ₹2,472 crore | ₹2,075 crore | +19% |
| Apollo 24/7 GMV | ₹682 crore | ₹554 crore | +23% |
| Pharmacy Store Count | 6,742 | 6,626 | +116 stores |
| Beds (Operational) | 8,030 | 7,835 | +195 beds |
| Occupancy Rate | 65% | 68% | -3% pts |
The hospital division remained Apollo’s largest revenue driver, generating ₹2,935 crore in Q1 FY26, up 11% from last year. EBITDA stood at ₹718 crore, with margins improving to 24.5%. The network’s 8,030 beds maintained healthy utilisation despite a slight dip in occupancy to 65% due to ongoing capacity expansion.
Apollo HealthCo, the group’s digital and pharmacy arm, posted ₹2,472 crore in revenue, up 19% YoY, and delivered a profit of ₹57 crore versus a ₹13 crore loss in Q1 FY25. Apollo Health and Lifestyle Ltd. also improved, narrowing its loss to ₹8 crore on a 19% revenue rise.
The company’s flagship digital health platform, Apollo 24/7, saw a 23% YoY increase in GMV to ₹682 crore, boosted by growing teleconsultation demand and e-pharmacy orders. During the quarter, 116 new pharmacy outlets were launched, taking the network to 6,742 stores nationwide.
Also Read: India’s Biggest Dividend Month: August Unfolds with Over ₹1,000 Crore in Payouts
Chairman Dr. Prathap C Reddy credited the robust performance to Apollo’s integrated ecosystem, strategic investments, and strong execution. “Our three growth engines — Healthcare Services, Retail Health & Diagnostics, and Digital & Pharma Distribution — are delivering meaningful contributions,” he noted.
Looking ahead, Apollo plans to invest ₹7,600 crore over the next five years to add more than 4,300 beds, with major expansions in Bengaluru and Hyderabad. The quarter also saw the launch of Apollo Zen, an AI-powered preventive health platform, and OraLife, a screening programme for early detection of oral cancer.
The board has approved the demerger of its digital health and pharmacy business into a new entity, Apollo Healthtech Ltd., aimed at unlocking value, optimising capital allocation, and driving focused growth in the rapidly evolving digital healthcare sector.
With solid financial momentum, diversified revenue streams, and a clear expansion roadmap, Apollo Hospitals is positioned to strengthen its leadership in India’s healthcare market while tapping growth opportunities in emerging geographies.
READ MORE ON
